Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study

Abstract

Background/aims To compare the effectiveness and side-effect profile of two doses of interferon alpha2b (IFNa2b) eye-drops (1 million international units (IU)/ml versus 3 million IU/ml) in the treatment of ocular surface squamous neoplasia (OSSN). Methods Retrospective case series. Results Thirty-five eyes were identified over an 11-year period (1996e2007). Twenty-one eyes (19 patients) with conjunctival intraepithelial neoplasia (CIN) were treated with 1 million IU/ml of topical IFN-a2b; 12 eyes (nine patients) with CIN were treated with 3 million IU/ ml. Two patients with squamous cell carcinoma (SCC) were treated with topical interferon, one with 1 million IU/ml and one with 3 million IU/ml. Baseline demographic information was not statistically different between the two groups. In patients with CIN, topical therapy eliminated disease in 81% of eyes in the 1 million IU/ml group versus 92%, in the 3 million IU/ml group, p¼0.41. The median time to OSSN resolution was 2.8 months in the 1 million IU/ml group and 1.9 months in the 3 million IU/ml group, p¼0.55. Neither eye with SCC responded to interferon therapy. Topical therapy was well tolerated. After a median follow-up of 24 months, three recurrences were seen in eyes successfully treated with topical therapy. Conclusion In our study, there were no significant differences between the 1 million IU/ml group and the 3 million IU/ml group for the treatment of CIN.

Preclinical evaluation of recombinant human IFNα2b-containing magnetoliposomes for treating hepatocellular carcinoma

“…26 It has been suggested that rhIFNα 2 b plays important roles in antitumor and antiviral activity and regulation of the immune system. 3,[8][9][10][11][12][13][14][15][16] The mechanism of the antitumor effect is not completely clear yet. However, studies have suggested it might inhibit tumor growth in vivo through tumor cellgrowth inhibition, tumor-cell apoptosis, oncogene-expression restraint, immune-system regulation, and tumor-angiogenesis suppression.…”

“…[5][6][7] Some studies show that IFNα, including IFNα 2 b, is also capable of exerting antitumor effects against HCC, hairy cell leukemia, lymphoma, melanoma, and breast cancer. 3,[8][9][10][11][12][13][14][15][16] However, an extensive clinical trial of IFNα 2 b for HCC was delayed, due to the weak therapeutic effect based on conventional drug-delivery methods. In general, these methods cause rapid degradation of IFNα 2 b in the body and induce severe side effects, due to the systemic distribution of drugs in the body causing bone marrow suppressions and neurologic disorders.…”

Szemfelszíni laphám-neoplasia

“…Az IFN-ek használata elterjedt a vesesejtes carcinoma, a melanoma malignum, a méhnyakrák, a fej-nyaki tumorok, a medullaris pajzsmirigy-carcinoma, a myeloma multiplex, a krónikus myeloid leukaemia, a hepatitis-B és a hepatitis-C kezelésében [42].…”

Topical Interferon Alfa-2b Treatment in Recurrence of Conjunctival Intraepithelial Neoplasia: Three Years Follow Up Results: Case Report

“…Literatürdeki ça-lışmalarda tedavi sonrası izlem süreleri 12-24 ay arasında değişmektedir. [7][8][9]12 Olgumuzun izlem süresi 36 ay olup, bu süre içinde nüks izlenmemiştir. Bu olgu ile topikal IFN alfa-2b tedavisinin etkili olduğu gözlemlenmiştir.…”